Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01105598 · ClinicalTrials.gov registry record · Phase 1
A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia
A Phase 1 study, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT01105598 is a Phase 1 study that has completed, run by Esperion Therapeutics. The registered enrollment target is 53 participants.
The verdict
NCT01105598, a Phase 1 study, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
This Phase 1, double-blind (sponsor open) study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of ETC-1002 given to subjects with mild dyslipidemia.
Interventions
- DRUG ETC-1002 or placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2010-04-20 |
| Est. Completion | 2010-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01105598
The ClinicalTrials.gov registry entry for NCT01105598 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esperion Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ETC-1002 or placebo is the first listed.
NCT01105598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01105598 about?
NCT01105598 is a clinical study titled "A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia". This Phase 1, double-blind (sponsor open) study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of ETC-1002 given to subjects with mild dyslipidemia.
What is the current status of trial NCT01105598?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2010-04-20. Estimated completion is 2010-10-02.
What interventions are being tested in trial NCT01105598?
The interventions under investigation include: ETC-1002 or placebo (DRUG).
Who is sponsoring clinical trial NCT01105598?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.